Status:
COMPLETED
Assessment of Translesional Markers and Metabolomics
Lead Sponsor:
Emory University
Collaborating Sponsors:
Boston Scientific Corporation
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
21+ years
Brief Summary
Blockages in the blood vessels of the heart are the main cause of chest pain, heart attacks, and sudden death. A cardiac catheterization, or injecting x-ray dye into the blood vessels of the heart and...
Detailed Description
Introduction Hypothesis Coronary heart disease is the leading cause of death in the United States, accounting for \> 500,000 lives each year. Atherosclerosis is the underlying mechanism for unstable...
Eligibility Criteria
Inclusion
- Men and women from the ages of 21 and older
- Able to give informed consent
- Already scheduled to undergo diagnostic catheterization or percutaneous coronary intervention
- A culprit lesion (\>60% diameter stenosis) in an artery that is at least 2.5 mm in diameter immediately proximal to the lesion.
- Presence of a second, non-culprit lesion, that is between 20 and 60% diameter stenosis in an artery that is at least 2.5 mm in diameter immediately proximal to the lesion.
Exclusion
- ST-segment elevation myocardial infarction
- Thrombolysis in Myocardial Infarction (TIMI) grade 0 flow in the vessel containing the culprit lesion
- Autoimmune diseases, malignancy, or with active infections
- Taking immune-modulating therapies, eg prednisone
- Culprit lesion is in-stent restenosis
- Culprit lesion cannot be crossed with a wire and/or balloon
- Those enrolled in another research study
Key Trial Info
Start Date :
April 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00321139
Start Date
April 1 2006
Last Update
December 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Hospital
Atlanta, Georgia, United States, 30322